In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.

FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...

FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, England (Reuters) - British drugmaker AstraZeneca said on Friday that the U.S. Food and Drug Administration (FDA) has approved ...

AstraZeneca announced it has received FDA approval for the self-administration of benralizumab in a prefilled, single-use auto-injector pen for patients with severe eosinophilic asthma, according to a ...